|
|
||||||||


*
Department of Dermatology, Kanazawa University School of Medicine, Kanazawa, Japan; and
Department of Immunology, Duke University Medical Center, Durham, NC 27710
Signaling thresholds influence the balance between humoral immunity
and autoimmunity. Cell surface CD19 regulates intrinsic and Ag
receptor-induced B lymphocyte signaling thresholds, and transgenic mice
that overexpress CD19 by 3-fold generate spontaneous autoantibodies in
a genetic background not associated with autoimmunity. To quantify the
extent that genetically determined differences in expression of a
single cell surface molecule can influence autoantibody production, we
have assessed autoimmunity in a C57BL/6-transgenic mouse line with
subtle 1529% increases in CD19 cell surface expression (CD19
transgenic). Antinuclear Abs, especially anti-spindle pole Abs,
rheumatoid factor, and autoantibodies for ssDNA, dsDNA, and histone
were produced in these transgenic mice, but not littermate controls.
This demonstrates that small changes in CD19 expression can induce
autoantibody production. Remarkably, similar changes in CD19 expression
were found on B cells from patients with systemic sclerosis, a
multisystem disorder of connective tissue with autoantibody production.
CD19 density on blood B cells from systemic sclerosis patients was
significantly (
20%) higher compared with normal individuals,
whereas CD20, CD22, and CD40 expression were normal. These results
suggest that modest changes in the expression or function of regulatory
molecules such as CD19 may shift the balance between tolerance and
immunity to autoimmunity. Thereby autoimmune disease may result from a
collection of subtle multigenic alterations that could include
incremental density changes in cell surface signaling
molecules.
This article has been cited by other articles:
![]() |
A. Yoshizaki, Y. Iwata, K. Komura, F. Ogawa, T. Hara, E. Muroi, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto, et al. CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma Am. J. Pathol., June 1, 2008; 172(6): 1650 - 1663. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsushita, M. Hasegawa, T. Matsushita, M. Fujimoto, M. Horikawa, T. Fujita, A. Kawasuji, F. Ogawa, D. A. Steeber, T. F. Tedder, et al. Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice J. Immunol., July 1, 2007; 179(1): 698 - 707. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Iwata, F. Ogawa, K. Komura, E. Muroi, T. Hara, K. Shimizu, M. Hasegawa, M. Fujimoto, Y. Tomita, and S. Sato Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress Rheumatology, May 1, 2007; 46(5): 790 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hasegawa, Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis Am. J. Pathol., September 1, 2006; 169(3): 954 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease PNAS, October 18, 2005; 102(42): 15178 - 15183. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yan, M. J. Wolff, J. Unternaehrer, I. Mellman, and M. J. Mamula Targeting antigen to CD19 on B cells efficiently activates T cells Int. Immunol., July 1, 2005; 17(7): 869 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Grimaldi, R. Hicks, and B. Diamond B Cell Selection and Susceptibility to Autoimmunity J. Immunol., February 15, 2005; 174(4): 1775 - 1781. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Asano, M. Fujimoto, N. Yazawa, S. Shirasawa, M. Hasegawa, H. Okochi, K. Tamaki, T. F. Tedder, and S. Sato B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin Mouse Am. J. Pathol., August 1, 2004; 165(2): 641 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Su, X. Li, J. C. Edberg, J. Wu, P. Ferguson, and R. P. Kimberly A Promoter Haplotype of the Immunoreceptor Tyrosine-Based Inhibitory Motif-Bearing Fc{gamma}RIIb Alters Receptor Expression and Associates with Autoimmunity. II. Differential Binding of GATA4 and Yin-Yang1 Transcription Factors and Correlated Receptor Expression and Function J. Immunol., June 1, 2004; 172(11): 7192 - 7199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hase, Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N. Tsuchiya, K. Tokunaga, N. Masawa, M. Azuma, et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex Blood, March 15, 2004; 103(6): 2257 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kess, T. Peters, J. Zamek, C. Wickenhauser, S. Tawadros, K. Loser, G. Varga, S. Grabbe, R. Nischt, C. Sunderkotter, et al. CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis J. Immunol., December 1, 2003; 171(11): 5697 - 5706. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. A. Mongini, A. E. Jackson, S. Tolani, R. J. Fattah, and J. K. Inman Role of Complement-Binding CD21/CD19/CD81 in Enhancing Human B Cell Protection from Fas-Mediated Apoptosis J. Immunol., November 15, 2003; 171(10): 5244 - 5254. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, S.-J. E. Beavitt, K. W. Harder, M. L. Hibbs, and D. M. Tarlinton The Activation and Subsequent Regulatory Roles of Lyn and CD19 After B Cell Receptor Ligation are Independent J. Immunol., December 15, 2002; 169(12): 6910 - 6918. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fujimoto, J. C. Poe, A. B. Satterthwaite, M. I. Wahl, O. N. Witte, and T. F. Tedder Complementary Roles for CD19 and Bruton's Tyrosine Kinase in B Lymphocyte Signal Transduction J. Immunol., June 1, 2002; 168(11): 5465 - 5476. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. HASLER and M. ZOUALI B cell receptor signaling and autoimmunity FASEB J, October 1, 2001; 15(12): 2085 - 2098. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hasegawa, M. Fujimoto, J. C. Poe, D. A. Steeber, and T. F. Tedder CD19 Can Regulate B Lymphocyte Signal Transduction Independent of Complement Activation J. Immunol., September 15, 2001; 167(6): 3190 - 3200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hasegawa, M. Fujimoto, J. C. Poe, D. A. Steeber, C. A. Lowell, and T. F. Tedder A CD19-Dependent Signaling Pathway Regulates Autoimmunity in Lyn-Deficient Mice J. Immunol., September 1, 2001; 167(5): 2469 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Youinou and P M Lydyard CD5/ B cells in nonorgan-specific autoimmune diseases: a fresh look Lupus, August 1, 2001; 10(8): 523 - 525. [PDF] |
||||
![]() |
M. Fujimoto, J. C. Poe, M. Hasegawa, and T. F. Tedder CD19 Amplification of B Lymphocyte Ca2+ Responses. A ROLE FOR Lyn SEQUESTRATION IN EXTINGUISHING NEGATIVE REGULATION J. Biol. Chem., November 21, 2001; 276(48): 44820 - 44827. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |